Zobrazeno 1 - 10 of 248 pro vyhledávání: '"Ducray R"'
1
Akademický článek
Crystal structure of (1aS,2S,3R)-2-trimethylsilyl-la,2,3,4-tetrahydrol-1H-8b-aza-benzo[a]cyclopropa[c]cyclohepten-3-ol, C14H21NOSi
Autor: Ducray R., Grosvalet L., Ciufolini M. A., Perrin M.
Publikováno v: Zeitschrift für Kristallographie - New Crystal Structures, Vol 216, Iss 1-4, Pp 371-372 (2001)
Externí odkaz: https://doaj.org/article/92eecfe5261b487097a0966a025c98fc
Zobrazit plný text záznamu
2
Akademický článek
Discovery of Ureido-Substituted 4-Phenylthiazole Derivatives as IGF1R Inhibitors with Potent Antiproliferative Properties.
Autor: Tian, Yuan1 (AUTHOR), An, Ni2 (AUTHOR), Li, Wenru1 (AUTHOR), Tang, Shixin1 (AUTHOR), Li, Jiqi1 (AUTHOR), Wang, He1 (AUTHOR), Su, Rongjian2 (AUTHOR) teachersurongjian@126.com, Cai, Dong1 (AUTHOR) teachersurongjian@126.com
Publikováno v: Molecules. Jun2024, Vol. 29 Issue 11, p2653. 18p.
Zobrazit plný text záznamu
3
Akademický článek
Correction to Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
Autor: Degorce SL, Barlaam B, Cadogan E, Dishington A, Ducray R, Glossop SC, Hassall LA, Lach F, Lau A, McGuire TM, Nowak T, Ouvry G, Pike KG, Thomason AG
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2018 Jul 26; Vol. 61 (14), pp. 6398. Date of Electronic Publication: 2018 Jul 03.
Zobrazit plný text záznamu
4
Akademický článek
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
Autor: Pike KG; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., Barlaam B; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., Cadogan E; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., Campbell A; Pharmaceutical Sciences , AstraZeneca , Silk Road Business Park, Macclesfield SK10 2NA , U.K., Chen Y; Oncology, IMED Biotech Unit , AstraZeneca , 35 Gatehouse Drive , Waltham , Massachusetts 02451 , United States., Colclough N; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., Davies NL; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., de-Almeida C; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., Degorce SL; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K.; Oncology, IMED Biotech Unit , AstraZeneca, Centre de Recherches, Z. I. la Pompelle , BP 1050, 51689 Reims Cedex 2 , France., Didelot M; Oncology, IMED Biotech Unit , AstraZeneca, Centre de Recherches, Z. I. la Pompelle , BP 1050, 51689 Reims Cedex 2 , France., Dishington A; Oncology, IMED Biotech Unit , AstraZeneca , Alderley Park , Macclesfield , Cheshire SK10 4TG , U.K., Ducray R; Oncology, IMED Biotech Unit , AstraZeneca, Centre de Recherches, Z. I. la Pompelle , BP 1050, 51689 Reims Cedex 2 , France., Durant ST; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., Hassall LA; Oncology, IMED Biotech Unit , AstraZeneca , Alderley Park , Macclesfield , Cheshire SK10 4TG , U.K., Holmes J; Oncology, IMED Biotech Unit , AstraZeneca , Alderley Park , Macclesfield , Cheshire SK10 4TG , U.K., Hughes GD; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., MacFaul PA; Oncology, IMED Biotech Unit , AstraZeneca , Alderley Park , Macclesfield , Cheshire SK10 4TG , U.K., Mulholland KR; Chemical Development , AstraZeneca , Silk Road Business Park , Macclesfield SK10 2NA , U.K., McGuire TM; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., Ouvry G; Oncology, IMED Biotech Unit , AstraZeneca, Centre de Recherches, Z. I. la Pompelle , BP 1050, 51689 Reims Cedex 2 , France., Pass M; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., Robb G; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., Stratton N; Discovery Sciences , AstraZeneca , Alderley Park , Macclesfield , Cheshire SK10 4TG , U.K., Wang Z; Pharmaron Beijing Co., Ltd. , 6 Taihe Road BDA , Beijing 100176 , P.R. China., Wilson J; Oncology, IMED Biotech Unit , AstraZeneca , Building 310, Cambridge Science Park, 319 Milton Road , Cambridge CB4 0WG , U.K., Zhai B; Pharmaron Beijing Co., Ltd. , 6 Taihe Road BDA , Beijing 100176 , P.R. China., Zhao K; Pharmaron Beijing Co., Ltd. , 6 Taihe Road BDA , Beijing 100176 , P.R. China., Al-Huniti N; Oncology, IMED Biotech Unit , AstraZeneca , 35 Gatehouse Drive , Waltham , Massachusetts 02451 , United States.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2018 May 10; Vol. 61 (9), pp. 3823-3841. Date of Electronic Publication: 2018 May 02.
Zobrazit plný text záznamu
5
Akademický článek
Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators: in vitro, molecular docking, molecular dynamics, and SAR studies.
Autor: Farouk, Faten1 (AUTHOR), Elmaaty, Ayman Abo2 (AUTHOR), Elkamhawy, Ahmed3,4 (AUTHOR), Tawfik, Haytham O.5 (AUTHOR), Alnajjar, Radwan6,7,8 (AUTHOR), Abourehab, Mohammed A. S.9 (AUTHOR), Saleh, Mohamed A.10,11 (AUTHOR), Eldehna, Wagdy M.12,13 (AUTHOR), Al‐Karmalawy, Ahmed A.1 (AUTHOR) akarmalawy@acu.edu.eg
Publikováno v: Journal of Enzyme Inhibition & Medicinal Chemistry. Dec2023, Vol. 38 Issue 1, p1-16. 16p.
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
Autor: Degorce SL; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.; Oncology Innovative Medicines Unit, AstraZeneca, Centre de Recherches , Z.I. la Pompelle, BP 1050, 51689 Reims Cedex 2, France., Barlaam B; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Cadogan E; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Dishington A; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Ducray R; Oncology Innovative Medicines Unit, AstraZeneca, Centre de Recherches , Z.I. la Pompelle, BP 1050, 51689 Reims Cedex 2, France., Glossop SC; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Hassall LA; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Lach F; Oncology Innovative Medicines Unit, AstraZeneca, Centre de Recherches , Z.I. la Pompelle, BP 1050, 51689 Reims Cedex 2, France., Lau A; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., McGuire TM; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Nowak T; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Ouvry G; Oncology Innovative Medicines Unit, AstraZeneca, Centre de Recherches , Z.I. la Pompelle, BP 1050, 51689 Reims Cedex 2, France., Pike KG; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Thomason AG; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2016 Jul 14; Vol. 59 (13), pp. 6281-92. Date of Electronic Publication: 2016 Jun 16.
Zobrazit plný text záznamu
8
Akademický článek
Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
Autor: Degorce SL; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.; Oncology Innovative Medicines Unit, AstraZeneca, Centre de Recherches , Z.I. la Pompelle, BP1050, 51689 Reims Cedex 2, France., Boyd S; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Curwen JO; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Ducray R; Oncology Innovative Medicines Unit, AstraZeneca, Centre de Recherches , Z.I. la Pompelle, BP1050, 51689 Reims Cedex 2, France., Halsall CT; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Jones CD; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.; Oncology Innovative Medicines Unit, AstraZeneca, Centre de Recherches , Z.I. la Pompelle, BP1050, 51689 Reims Cedex 2, France., Lach F; Oncology Innovative Medicines Unit, AstraZeneca, Centre de Recherches , Z.I. la Pompelle, BP1050, 51689 Reims Cedex 2, France., Lenz EM; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Pass M; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Pass S; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Trigwell C; Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2016 May 26; Vol. 59 (10), pp. 4859-66. Date of Electronic Publication: 2016 Apr 22.
Zobrazit plný text záznamu
9
Correction to Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators.
Autor: Degorce SL, Bailey A, Callis R, De Savi C, Ducray R, Lamont G, MacFaul P, Maudet M, Martin S, Morgentin R, Norman RA, Peru A, Pink JH, Plé PA, Roberts B, Scott JS
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2016 Apr 14; Vol. 59 (7), pp. 3576. Date of Electronic Publication: 2016 Mar 22.
Zobrazit plný text záznamu
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje